TY - JOUR
T1 - Mantle-cell lymphoma
AU - Barista, Ibrahim
AU - Romaguera, Jorge E.
AU - Cabanillas, Fernando
PY - 2001/3/1
Y1 - 2001/3/1
N2 - During the past decade, mantle-cell lymphoma has been established as a new disease entity. The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles. These cells have small to medium-sized nuclei, are commonly indented or cleaved, and stain positively with CD5, CD20, cyclin D1, and FMC7 antibodies. Because of its morphological appearance and a resemblance to other low-grade lymphomas, many of which grow slowly, this lymphoma was initially thought to be an indolent tumour, but its natural course was not thoroughly investigated until the 1990s, when the BCL1 oncogene was identified as a marker for this disease. Mantle-cell lymphoma is a discrete entity, unrelated to small lymphocytic or small-cleaved-cell lymphomas.
AB - During the past decade, mantle-cell lymphoma has been established as a new disease entity. The normal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the lymph node, a thin layer surrounding the germinal follicles. These cells have small to medium-sized nuclei, are commonly indented or cleaved, and stain positively with CD5, CD20, cyclin D1, and FMC7 antibodies. Because of its morphological appearance and a resemblance to other low-grade lymphomas, many of which grow slowly, this lymphoma was initially thought to be an indolent tumour, but its natural course was not thoroughly investigated until the 1990s, when the BCL1 oncogene was identified as a marker for this disease. Mantle-cell lymphoma is a discrete entity, unrelated to small lymphocytic or small-cleaved-cell lymphomas.
UR - http://www.scopus.com/inward/record.url?scp=0035296352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035296352&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(00)00255-2
DO - 10.1016/S1470-2045(00)00255-2
M3 - Review article
C2 - 11902564
AN - SCOPUS:0035296352
SN - 1470-2045
VL - 2
SP - 141
EP - 148
JO - Lancet Oncology
JF - Lancet Oncology
IS - 3
ER -